针对复发或难治性弥漫大B细胞淋巴瘤新药——Tafasitamab

Tafasitamab:A New Drug for Recurrent or Refractory Diffuse Large B Cell Lymphoma

Tafasitamab(Tafasitamab-cxix;MONJUVI)是一种针对CD19的Fc工程化IgG1的抗体,通常与来那度胺联合使用.它主要用于治疗B细胞恶性肿瘤——复发或难治性弥漫大B细胞淋巴瘤(r/r DLBCL)和慢性淋巴细胞白血病(CLL),还包括由低级淋巴瘤引起的r/r DLBCL.这种药物还被用于包括滤泡性淋巴瘤和非霍奇金淋巴瘤(non-Hodgkin′s lymphoma,NHL)在内的多种B细胞恶性肿瘤治疗的临床研究.2020年7月美国食品药品监督管理局(FDA)批准了Tafasitamab上市,这是美国批准的第一个作为该群体二线治疗的药物.本文主要就Tafasitamab的临床药理学、临床研究、不良反应概况和用药注意事项等进行了介绍.

Tafasitamab(Tafasitamab-cxix;MONJUVI)is an antibody that targets CD19′s Fc engineered IgG1,which is used in combination with lenalidomide.It is used for the treatment of B cell malignancies-recurrent or refractory diffuse large B cell lymphoma(r/r DLBCL),chronic lymphocytic leukemia(CLL)and r/r DLBCL caused by low-level lymphoma.Tafasitamab is being studied in the treatment of follicular lymphoma and non-Hodgkin′s lymphoma.In July 2020,the Food and Drug Administration approved Tafasitamab which is the first drug in the United States as a second line treatment for the group.This paper introduces the clinical pharmacology,clinical studies,adverse drug reactions,and precautions of Tafasitamab.